| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Pseudolaric acid A-O-β-D-glucopyranoside targets fungal pathogens through its antifungal activity. It also exhibits antifertility activity. As a diterpene lactone, the compound likely interacts with cellular membranes and may inhibit specific enzymes or signaling pathways in target organisms. The exact molecular targets have not been fully characterized, but the compound's biological activities have been documented in natural product studies.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Pseudolaric acid A-O-β-D-glucopyranoside exhibits antifungal activity. The compound shows activity against various fungal species, consistent with its isolation from Cortex Pseudolaricis, a traditional Chinese medicinal material used for its antifungal properties. The compound also demonstrates antifertility activity in relevant in vitro models. The glucoside moiety may affect the compound's solubility and bioavailability compared to the aglycone form.
|
| ln Vivo |
In vivo studies of Pseudolaric acid A-O-β-D-glucopyranoside have demonstrated its antifungal and antifertility activities. The compound's isolation from Cortex Pseudolaricis, a plant material with traditional medicinal uses, suggests in vivo efficacy in relevant disease models. The antifungal activity has been studied in models of fungal infections. The antifertility activity has been evaluated in animal models. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic profile, as well as its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for Pseudolaric acid A-O-β-D-glucopyranoside typically involve antifungal susceptibility testing using standardized methods such as CLSI (Clinical and Laboratory Standards Institute) broth microdilution or agar dilution assays. Various fungal strains are cultured in appropriate media and exposed to serial dilutions of the compound (0.125-128 μg/mL). Minimum inhibitory concentrations (MIC) are determined as the lowest concentration that inhibits visible fungal growth after 24-48 hours of incubation at appropriate temperatures. For mechanistic studies, the compound may be tested for inhibition of fungal enzymes or cell wall synthesis using biochemical assays. Positive controls (e.g., amphotericin B, fluconazole) are included for assay validation.
|
| Cell Assay |
For in vitro cell-based assays, fungal cells or relevant mammalian cell lines are cultured in appropriate media. For antifungal activity, fungal cells (e.g., Candida albicans, Aspergillus species) are treated with Pseudolaric acid A-O-β-D-glucopyranoside at concentrations ranging from 0.125-128 μg/mL. Fungal growth is monitored by measuring optical density at 600 nm, and MIC values are determined. For antifertility studies, relevant cell lines (e.g., reproductive cells) are treated with the compound and cell viability, proliferation, and function are assessed. Cytotoxicity in mammalian cells is evaluated using MTT or CCK-8 assays to determine the selectivity index. Apoptosis may be assessed by flow cytometry.
|
| Animal Protocol |
In vivo animal studies with Pseudolaric acid A-O-β-D-glucopyranoside typically use mouse or rat models. For antifungal studies, animals are infected with pathogenic fungi (e.g., via intravenous or intraperitoneal injection) and treated with the compound orally or intraperitoneally at doses ranging from 1-50 mg/kg daily for 7-14 days. Survival rates, fungal burden in tissues, and histopathological changes are assessed. For antifertility studies, rodents are treated with the compound and reproductive parameters (fertility rate, litter size, sperm count, hormonal levels) are evaluated. Organ weights and histopathology are examined at study endpoint. Vehicle control and positive control groups are included.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Pseudolaric acid A-O-β-D-glucopyranoside have not been fully characterized. As a glucoside (molecular weight 550.59 g/mol, C₂₈H₃₈O₁₁), the compound is expected to have moderate oral bioavailability. The glucoside moiety may be hydrolyzed by gut microbiota to release the aglycone, which may be the active form. The compound has a predicted density of approximately 1.37 g/cm³ and is essentially neutral. Tissue distribution and elimination pathways are not well documented. The compound is typically handled as a research chemical with storage at 2-8°C or -20°C.
|
| Toxicity/Toxicokinetics |
Pseudolaric acid A-O-β-D-glucopyranoside is considered to have a moderate toxicity profile typical of natural product diterpenes. In antifungal studies, the compound has shown efficacy at concentrations that are not overtly toxic to mammalian cells, suggesting a favorable selectivity index. However, detailed toxicity studies have not been published. As a compound from a traditional medicinal plant, it has a history of use in traditional Chinese medicine, though the purified compound's toxicity may differ from the crude extract. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
It has been reported that PseudolaricacidAbeta-D-glucoside exists in Pseudolaricix amabilis and Larix kaempferi, and there is relevant data.
Pseudolaric acid A-O-β-D-glucopyranoside is a natural compound isolated from Cortex Pseudolaricis (the root bark of Pseudolarix amabilis), a plant used in traditional Chinese medicine. It is a diterpene lactone glucoside. The compound demonstrates antifungal and antifertility activities. It is also known as土荆皮甲酸-O-β-D-葡萄糖苷 in Chinese. The compound is intended for research purposes only and is not approved as a therapeutic drug. Its mechanism of action and full pharmacological profile remain areas of ongoing research. |
| Molecular Formula |
C28H38O11
|
|---|---|
| Molecular Weight |
550.5947
|
| Exact Mass |
550.241
|
| CAS # |
98891-44-2
|
| PubChem CID |
44566375
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
730.4±60.0 °C at 760 mmHg
|
| Flash Point |
237.2±26.4 °C
|
| Vapour Pressure |
0.0±5.4 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
39
|
| Complexity |
1100
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC1=CC[C@]23CC[C@H]([C@]2(CC1)OC(=O)C)[C@@](OC3=O)(C)/C=C/C=C(\C)/C(=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
IVYWRYGMQNKDQB-VHJBJYHKSA-N
|
| InChi Code |
InChI=1S/C28H38O11/c1-15-7-11-27-12-9-19(28(27,13-8-15)38-17(3)30)26(4,39-25(27)35)10-5-6-16(2)23(34)37-24-22(33)21(32)20(31)18(14-29)36-24/h5-7,10,18-22,24,29,31-33H,8-9,11-14H2,1-4H3/b10-5+,16-6+/t18-,19+,20-,21+,22-,24+,26-,27-,28+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (2E,4E)-5-[(1R,7S,8S,9R)-7-acetyloxy-4,9-dimethyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8162 mL | 9.0812 mL | 18.1623 mL | |
| 5 mM | 0.3632 mL | 1.8162 mL | 3.6325 mL | |
| 10 mM | 0.1816 mL | 0.9081 mL | 1.8162 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
